Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis

• Published in: Frontiers in oncology Vol. 9; p. 95
• Main Authors: Yu, Dandan, Tong, Yan, Guo, Xinnian, Feng, Lingfang, Jiang, Zhaoqiang, Ying, Shibo, Jia, Junlin, Fang, Yuan, Yu, Min, Xia, Hailing, Shi, Li, Lou, Jianlin
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.03.2019
• Subjects: breast cancer; circulating cell-free DNA; concentration; diagnostic value; meta-analysis; Oncology; meta-analysis; breast cancer; concentration; diagnostic value; circulating cell-free DNA
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2019.00095

The diagnostic value of the concentration of circulating cell-free DNA (cfDNA) for breast cancer has generated inconsistent results. The aim of this study was to evaluate the first diagnostic value of the concentration of cfDNA for breast cancer by meta-analysis. Studies were retrieved by searching PubMed, Cochrane Library, and Web of Science before June 2018. Sensitivity, specificity, diagnostic odds ratio (DOR), the summary receiver operating characteristic (SROC) curve, and the area under curve (AUC) were used to summarize overall diagnostic performance. The random-effects model was used to calculate the pooled statistics. Subgroup analysis and meta-regression analysis were carried out to detect the source of heterogeneity. A total of 13 studies were identified with 1,087 breast cancer patients and 720 healthy controls. Overall, the pooled sensitivity and specificity of concentration of cfDNA for breast cancer were 87% (95% CI, 73-94%) and 87% (95% CI, 79-93%), respectively. The pooled DOR was 32.93 (95% CI, 13.52-80.19) and the SROC curve revealed an AUC of 0.93 (95% CI, 0.91-0.95). Meta-regression analysis showed that no covariate had a significant correlation with relative DOR (RDOR). Publication bias was not detected in this meta-analysis. This meta-analysis indicates that the concentration of cfDNA has potential first diagnostic value for breast cancer and plasma may be a better source of cfDNA for detection of breast cancer.